Clinical Parkinsonism Related Disorders最新文献_第10页

Effects of a rollator on fall prevention in Community-Dwelling people with Parkinson’s Disease: A prospective cohort study 滚动器对帕金森病社区居民跌倒预防的影响：一项前瞻性队列研究

Clinical Parkinsonism Related Disorders Pub Date : 2023-01-01 DOI: 10.1016/j.prdoa.2023.100190

Kohei Okuyama , Yoshimi Matuo

引用次数: 0

Levodopa responsive gait dynamics in OFF- and ONOFF-state freezing of gait in Parkinson’s disease 左旋多巴反应步态动力学在帕金森病的关闭和关闭状态冻结步态

Clinical Parkinsonism Related Disorders Pub Date : 2023-01-01 DOI: 10.1016/j.prdoa.2023.100202

Tuhin Virmani , Lakshmi Pillai , Aliyah Glover , Reid D. Landes

{"title":"Levodopa responsive gait dynamics in OFF- and ONOFF-state freezing of gait in Parkinson’s disease","authors":"Tuhin Virmani , Lakshmi Pillai , Aliyah Glover , Reid D. Landes","doi":"10.1016/j.prdoa.2023.100202","DOIUrl":"10.1016/j.prdoa.2023.100202","url":null,"abstract":"<div><h3>Background</h3><p>In people with Parkinson’s disease (PwPD), Freezing of Gait (FOG) episodes can be levodopa responsive (OFF-FOG) or levodopa unresponsive (ONOFF-FOG). Steady-state gait abnormalities, outside of the freezing episodes themselves also exist and the response to levodopa in these different groups has not been previously documented.</p></div><div><h3>Objectives</h3><p>To define the levodopa responsiveness in steady-state gait in OFF-FOG and ONOFF-FOG individuals.</p></div><div><h3>Methods</h3><p>Steady-state gait was collected in both the effective levodopa OFF-state (doses withheld > 8 h) and ON-state (1 h after levodopa dosing) in 32 PwPD; 10 with OFF-FOG and 22 with ONOFF-FOG. Levodopa response was compared between the two groups in the mean and variability (CV) of 8 spatiotemporal gait parameters.</p></div><div><h3>Results</h3><p>Both OFF-FOG and ONOFF-FOG participants showed improvement in mean stride-length and stride-velocity with levodopa. Improvement was seen in the OFF-FOG but not the ONOFF-FOG groups in mean stride-width and CV Integrated pressure with levodopa.</p></div><div><h3>Discussion</h3><p>In this study we show that steady-state gait deficits improve with levodopa in PwPD with OFF-FOG and ONOFF-FOG, even though episodes of FOG did not resolve in the ONOFF-FOG group. Lowering levodopa in people with ONOFF-FOG, or levodopa-unresponsive freezing of gait, should be undertake with caution and objective gait titration at different levodopa doses may be beneficial. Further work is needed to elucidate the pathophysiologic mechanisms of these differences.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/c5/main.PMC10241963.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9600565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” 帕金森病中葡萄糖脑苷酶突变和尿酸水平:一项潜在生物标志物的3年研究

Clinical Parkinsonism Related Disorders Pub Date : 2023-01-01 DOI: 10.1016/j.prdoa.2022.100177

Mehrdad Mozafar , Sina Kazemian , Elahe Hoseini , Mohammad Mohammadi , Rojina Alimoghadam , Mahan Shafie , Mahsa Mayeli , The Parkinson's Progression Markers Initiative

{"title":"The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker”","authors":"Mehrdad Mozafar , Sina Kazemian , Elahe Hoseini , Mohammad Mohammadi , Rojina Alimoghadam , Mahan Shafie , Mahsa Mayeli , The Parkinson's Progression Markers Initiative","doi":"10.1016/j.prdoa.2022.100177","DOIUrl":"10.1016/j.prdoa.2022.100177","url":null,"abstract":"<div><h3>Background</h3><p>Blood uric acid level indicates an emerging biomarker in Parkinson's disease (PD). This study aimed to evaluate longitudinal uric acid levels among different kinds of glucocerebrosidase (GBA) mutations and to compare it among sporadic PD, genetic cohort Parkinson's disease (GENPD), genetic cohort unaffected (GENUN), and healthy control (HC) patients.</p></div><div><h3>Methods</h3><p>We conducted a study on 654 individuals from the Parkinson's progression markers initiative (PPMI) database. Baseline characteristics, uric acid levels, movement disorder society unified Parkinson's disease rating scale III (MDS-UPDRS III), Hoehn and Yahr Parkinson stage (H&Y stage), and DaT scan specific binding ratio (SBR) data were obtained. Different GBA mutations were collected and categorized into three groups. Longitudinal measurements of uric acid and MDS-UPDRS III score were evaluated during 3-years of follow-up.</p></div><div><h3>Result</h3><p>GENPD cohort exhibited a greater MDS-UPDRS III score, H&Y stage, and lower SBR in the right caudate, left caudate, and right putamen compared to sporadic PD. Baseline uric acid level was similar among all groups and different GBA variants. After adjustment for age, sex, and body mass index, the uric acid level was significantly lower in the GENPD group than in HC during year 2 (P-value: 0.009). No significant longitudinal differences were detected for the MDS-UPDRS III score and three groups of GBA mutations.</p></div><div><h3>Conclusion</h3><p>This is the first study to assess uric acid levels and MDS-UPDRS III scores among different GBA mutation variants within 3 years of follow-up. We found similar clinical characteristics among different subtypes of GBA mutations.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10472147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case clusters of Parkinson’s disease 帕金森病的病例群

Clinical Parkinsonism Related Disorders Pub Date : 2023-01-01 DOI: 10.1016/j.prdoa.2023.100211

E. Fuller Torrey, Judy Miller, Ann Bowler

引用次数: 0

Neurologic and psychiatric features of impending neurodegeneration in iRBD iRBD患者即将发生的神经退行性变的神经和精神特征

Clinical Parkinsonism Related Disorders Pub Date : 2023-01-01 DOI: 10.1016/j.prdoa.2023.100216

Daniel A. Barone , Harini Sarva , Natalie Hellmers , Fei Wang , Zhenxing Xu , Ana C. Krieger , Claire Henchcliffe

{"title":"Neurologic and psychiatric features of impending neurodegeneration in iRBD","authors":"Daniel A. Barone , Harini Sarva , Natalie Hellmers , Fei Wang , Zhenxing Xu , Ana C. Krieger , Claire Henchcliffe","doi":"10.1016/j.prdoa.2023.100216","DOIUrl":"10.1016/j.prdoa.2023.100216","url":null,"abstract":"<div><h3>Introduction</h3><p>Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is linked to Parkinson’s disease and other alpha-synucleinopathies, but various subsets of iRBD may not carry equal risk (i.e., those with depression are at higher risk than those without). Here, we prospectively focus on neurologic and psychiatric aspects of subjects with iRBD, in an attempt to determine what factors are prominent in those who undergo phenoconversion as opposed to those who do not.</p></div><div><h3>Methods</h3><p>We analyzed data from the “REM Sleep Behavior Disorder Associations with Parkinson’s Disease Study (RAPiDS)” cohort both at baseline and then at follow-up evaluations (1 to 3 years later) utilizing several neurologic batteries, including the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the Montreal Cognitive Assessment (MoCA), the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP), the 10-M Walk Test (10MWT), and the Epworth Sleepiness Scale. Determination of phenoconversion was ascertained from physical examination and medical chart review from the initial evaluation onward.</p></div><div><h3>Results</h3><p>Of those who completed both evaluations, there were 33 subjects with iRBD, with an average age of 63.1 ± 12.8 years, with 9 women and 24 men. Of these, 8 (24%) iRBD subjects developed neurodegenerative illness, and demonstrated multiple areas of neurologic and psychiatric signs and symptoms, such as speech and movement problems as well as anxiety and depression.</p></div><div><h3>Conclusions</h3><p>Our data adds to the literature regarding risk of phenoconversion in those with iRBD. Further study will be needed, but it is clear that not all subjects with iRBD present the same risk for neurodegeneration.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/f2/main.PMC10480303.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10177229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of outpatient gastroenterology consult on pharmacotherapy and management of gastrointestinal symptoms in Parkinson’s Disease 门诊胃肠病学会诊对帕金森病胃肠道症状药物治疗和管理的影响

Clinical Parkinsonism Related Disorders Pub Date : 2023-01-01 DOI: 10.1016/j.prdoa.2023.100215

Jocelyn J. Chang , Sanjay R.V. Gadi , Aleksandar Videnovic , Braden Kuo , Trisha S. Pasricha

{"title":"Impact of outpatient gastroenterology consult on pharmacotherapy and management of gastrointestinal symptoms in Parkinson’s Disease","authors":"Jocelyn J. Chang , Sanjay R.V. Gadi , Aleksandar Videnovic , Braden Kuo , Trisha S. Pasricha","doi":"10.1016/j.prdoa.2023.100215","DOIUrl":"10.1016/j.prdoa.2023.100215","url":null,"abstract":"<div><h3>Background & aims</h3><p>Gastrointestinal (GI) symptoms are common in Parkinson’s Disease (PD) patients, and GI dysmotility is thought to induce motor fluctuations, requiring escalation of levodopa therapy. The role of GI consultation in managing such symptoms, however, is unclear. In this study, we investigate the possible association between GI dysmotility symptoms and escalated LEDD therapy, as well as factors associated with GI consultation for PD symptom management.</p></div><div><h3>Methods</h3><p>This was a retrospective case-study of 248 PD patients evaluated by outpatient neurology at Massachusetts General Brigham Healthcare from 2018 to 2022. Logistic regression, <em>t</em>-test, and Fisher exact tests were performed to identify factors associated with GI consult, change in LEDD with consult, and association of consultation with GI diagnoses and treatments, respectively.</p></div><div><h3>Results</h3><p>Among 248 PD patients, 12.9% received GI consultation despite 96.8% having GI symptoms. Bloating was the primary symptom associated with receiving GI consultation (OR 3.59 [95% CI 1.47–8.88], <em>p</em> = 0.005). GI consultation increased the odds of receiving GI-specific medications (78.2% vs 46.3%, <em>p</em> = 0.001) and specialized GI diagnoses like gastroparesis (9.4% vs 0.46%, <em>p</em> < 0.001) and pelvic floor dysfunction (15.6% vs 0%, <em>p</em> < 0.0001). Interestingly, LEDD tended not to change after GI consultation, and dysmotility symptoms, including bloating, did not predict need for higher LEDD.</p></div><div><h3>Conclusions</h3><p>While treating symptoms of dysmotility may not ameliorate levodopa-based motor fluctuations as much as previously thought, GI consultations are underutilized in PD, and patients who receive GI consultation are more likely to have changes in GI diagnosis and treatment.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10243991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of startle and related disorders 惊吓及相关病症的治疗。

Clinical Parkinsonism Related Disorders Pub Date : 2023-01-01 DOI: 10.1016/j.prdoa.2023.100218

Thien Thien Lim , Chia Yin Por , Yuan Ye Beh , Jie Ping Schee , Ai Huey Tan

引用次数: 0

Tremulous spastic ataxia in a patient with a homozygous truncating SYNE1 variant 一例具有纯合截短型SYNE1变体的患者的震颤性痉挛性共济失调

Clinical Parkinsonism Related Disorders Pub Date : 2023-01-01 DOI: 10.1016/j.prdoa.2023.100205

Francesca Spagnolo , Edoardo Monfrini , Vincenza Pinto , Giovanni Di Maggio , Paolo De Marco , Giacomo P. Comi , Augusto Rini , Alessio Di Fonzo

引用次数: 0

Empowered patient: A program to improve people with Parkinson’s communication with health care professionals 授权病人:一个改善帕金森患者与卫生保健专业人员沟通的项目

Clinical Parkinsonism Related Disorders Pub Date : 2022-01-01 DOI: 10.1016/j.prdoa.2022.100156

Muhammed Shahriar Zaman , Setareh Ghahari , Mary Ann McColl

{"title":"Empowered patient: A program to improve people with Parkinson’s communication with health care professionals","authors":"Muhammed Shahriar Zaman , Setareh Ghahari , Mary Ann McColl","doi":"10.1016/j.prdoa.2022.100156","DOIUrl":"10.1016/j.prdoa.2022.100156","url":null,"abstract":"<div><h3>Background</h3><p>Communication breakdown between patients and health care professionals poses an accessibility gap preventing adequate health care. The Empowered Patient Program was developed to support people with Parkinson’s in improving their health communication skills/strategies and thus facilitate the accessibility gap in their care.</p></div><div><h3>Objective</h3><p>Our pilot study aimed to test the feasibility and preliminary effect of the Empowered Patient Program within a small cohort of individuals with Parkinson’s disease.</p></div><div><h3>Methods</h3><p>We completed a pre-test-post-test pilot study. Eight participants completed the Empowered Patient Program for this pilot study. Data collection was completed by administering a questionnaire prior to the program, immediately after program completion, and three months post-completion. We additionally conducted two telephone interviews with the participants to qualitatively gather feedback on the program.</p></div><div><h3>Results</h3><p>The program elucidated statistically significant improvement across domains/areas of knowledge (p = 0.01) and self-perceived communication skills (p = 0.04) among the participants. Through feedback from the patient interviews, it was confirmed that these significant improvements were owed largely to the high level of organization, intuitive user interface, and suitable content of the program for this cohort.</p></div><div><h3>Conclusions</h3><p>The Empowered Patient Program pilot resulted in a desired outcome indicating its satisfactory development. The next steps are to test the Empowered Patient program in a larger sample.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40551586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential role of the cardiac MIBG scan in differentiating the drug-induced Parkinsonism from Parkinson’s disease 心脏MIBG扫描在鉴别药物性帕金森病与帕金森病中的潜在作用

Clinical Parkinsonism Related Disorders Pub Date : 2022-01-01 DOI: 10.1016/j.prdoa.2022.100130

Mahan Shafie , Mahsa Mayeli , Samira Saeidi , Zahra Mirsepassi , Mehrshad Abbasi , Melika Shafeghat , Vajiheh Aghamollaii

{"title":"The potential role of the cardiac MIBG scan in differentiating the drug-induced Parkinsonism from Parkinson’s disease","authors":"Mahan Shafie , Mahsa Mayeli , Samira Saeidi , Zahra Mirsepassi , Mehrshad Abbasi , Melika Shafeghat , Vajiheh Aghamollaii","doi":"10.1016/j.prdoa.2022.100130","DOIUrl":"10.1016/j.prdoa.2022.100130","url":null,"abstract":"<div><h3>Introduction</h3><p>Considering the difficulties of differentiating Parkinson’s disease (PD) from drug-induced Parkinsonism (DIP) in patients receiving antipsychotics, developing robust diagnostic tools is essential. Herein, we used the metaiodobenzylguanidine (MIBG) scan to assess its diagnostic accuracy for this purpose.</p></div><div><h3>Methods</h3><p>44 DIP patients and 32 patients with PD as controls were enrolled. All the participants underwent a cardiac <sup>131</sup>I-MIBG scan. Statistical analysis was conducted to determine the significance of the results, and accuracy analyses were conducted to calculate the related sensitivity and specificity of the MIBG scan.</p></div><div><h3>Results</h3><p>The mean age of PD and DIP groups were 62.6 ± 5.9 and 51.5 ± 10.8 years, respectively. The mean duration of drug consumption in the DIP group was 52.2 ± 29.4 days (the mean interval between drug initiation and DIP onset was 28.5 ± 20.5). Symptoms relief occurred 40 ± 24.2 days after drug discontinuation. In the PD group, 15.6% showed negative and 84.4% positive results on the MIBG scan. In the DIP group, 86.4% were negative, and the remaining were positive. The difference in MIBG uptake between the two groups was statistically significant (P-value < 0.001). The sensitivity and specificity of the MIBG scan were 84.4% (CI: 84.0–84.8) and 86.36% (CI: 86.0–86.7) for the diagnosis of PD, respectively.</p></div><div><h3>Conclusion</h3><p>Our results indicated more positive MIBG scans in the PD group than the DIP. Also, the MIBG scan’s sensitivity and specificity in differentiating the PD are acceptable. Future works should assess these findings and the role of the MIBG scan in prognosis assessment of DIP and better allocation of the patients to related disciplines.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/33/15/main.PMC8802054.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39785471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2